Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Chromoanasynthesis is a common mechanism that leads to ERBB2 amplifications in a cohort of early stage HER2+ breast cancer samples.

Vasmatzis G, Wang X, Smadbeck JB, Murphy SJ, Geiersbach KB, Johnson SH, Gaitatzes AG, Asmann YW, Kosari F, Borad MJ, Serie DJ, McLaughlin SA, Kachergus JM, Necela BM, Thompson EA.

BMC Cancer. 2018 Jul 13;18(1):738. doi: 10.1186/s12885-018-4594-0.

2.

Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer.

Norton N, Fox N, McCarl CA, Tenner KS, Ballman K, Erskine CL, Necela BM, Northfelt D, Tan WW, Calfa C, Pegram M, Colon-Otero G, Perez EA, Clynes R, Knutson KL.

Breast Cancer Res. 2018 Jun 14;20(1):52. doi: 10.1186/s13058-018-0989-8.

3.

Breast Cancer Clinical Trial of Chemotherapy and Trastuzumab: Potential Tool to Identify Cardiac Modifying Variants of Dilated Cardiomyopathy.

Serie DJ, Crook JE, Necela BM, Axenfeld BC, Dockter TJ, Colon-Otero G, Perez EA, Thompson EA, Norton N.

J Cardiovasc Dev Dis. 2017 May 4;4(2). pii: E6. doi: 10.3390/jcdd4020006.

4.

Comprehensive Genomic Profiling of a Rare Thyroid Follicular Dendritic Cell Sarcoma.

Davila JI, Starr JS, Attia S, Wang C, Knudson RA, Necela BM, Sarangi V, Sun Z, Ren Y, Casler JD, Menke DM, Oliver GR, Joseph RW, Copland JA, Parker AS, Kocher JA, Thompson EA, Smallridge RC, Asmann YW.

Rare Tumors. 2017 Sep 15;9(2):6834. doi: 10.4081/rt.2017.6834. eCollection 2017 Jul 3.

5.

Cadherin complexes recruit mRNAs and RISC to regulate epithelial cell signaling.

Kourtidis A, Necela B, Lin WH, Lu R, Feathers RW, Asmann YW, Thompson EA, Anastasiadis PZ.

J Cell Biol. 2017 Oct 2;216(10):3073-3085. doi: 10.1083/jcb.201612125. Epub 2017 Sep 6.

6.

Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial.

Serie DJ, Crook JE, Necela BM, Dockter TJ, Wang X, Asmann YW, Fairweather D, Bruno KA, Colon-Otero G, Perez EA, Thompson EA, Norton N.

Pharmacogenet Genomics. 2017 Oct;27(10):378-385. doi: 10.1097/FPC.0000000000000302.

7.

Corrigendum: Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth.

Holst F, Hoivik EA, Gibson WJ, Taylor-Weiner A, Schumacher SE, Asmann YW, Grossmann P, Trovik J, Necela BM, Thompson EA, Meyerson M, Beroukhim R, Salvesen HB, Cherniack AD.

Sci Rep. 2017 Jun 30;7:46873. doi: 10.1038/srep46873.

8.

The antineoplastic drug, trastuzumab, dysregulates metabolism in iPSC-derived cardiomyocytes.

Necela BM, Axenfeld BC, Serie DJ, Kachergus JM, Perez EA, Thompson EA, Norton N.

Clin Transl Med. 2017 Dec;6(1):5. doi: 10.1186/s40169-016-0133-2. Epub 2017 Jan 18.

9.

Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial.

Perez EA, Ballman KV, Mashadi-Hossein A, Tenner KS, Kachergus JM, Norton N, Necela BM, Carr JM, Ferree S, Perou CM, Baehner F, Cheang MC, Thompson EA.

J Natl Cancer Inst. 2016 Oct 28;109(2). pii: djw207. Print 2017 Feb.

10.

Corrigendum: Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth.

Holst F, Hoivik EA, Gibson WJ, Taylor-Weiner A, Schumacher SE, Asmann YW, Grossmann P, Trovik J, Necela BM, Thompson EA, Meyerson M, Beroukhim R, Salvesen HB, Cherniack AD.

Sci Rep. 2016 Jun 24;6:27960. doi: 10.1038/srep27960. No abstract available.

11.

Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth.

Holst F, Hoivik EA, Gibson WJ, Taylor-Weiner A, Schumacher SE, Asmann YW, Grossmann P, Trovik J, Necela BM, Thompson EA, Meyerson M, Beroukhim R, Salvesen HB, Cherniack AD.

Sci Rep. 2016 May 10;6:25521. doi: 10.1038/srep25521. Erratum in: Sci Rep. 2016 Jun 24;6:27960. Sci Rep. 2017 Jun 30;7:46873.

12.

Assessment of Tumor Heterogeneity, as Evidenced by Gene Expression Profiles, Pathway Activation, and Gene Copy Number, in Patients with Multifocal Invasive Lobular Breast Tumors.

Norton N, Advani PP, Serie DJ, Geiger XJ, Necela BM, Axenfeld BC, Kachergus JM, Feathers RW, Carr JM, Crook JE, Moreno-Aspitia A, Anastasiadis PZ, Perez EA, Thompson EA.

PLoS One. 2016 Apr 14;11(4):e0153411. doi: 10.1371/journal.pone.0153411. eCollection 2016.

13.

Correction: Folate receptor-α (FOLR1) expression and function in triple negative tumors.

Necela BM, Crozier JA, Andorfer CA, Lewis-Tuffin L, Kachergus JM, Geiger XJ, Kalari KR, Serie DJ, Sun Z, Moreno-Aspitia A, O'Shannessy DJ, Maltzman JD, McCullough AE, Pockaj BA, Cunliffe HE, Ballman KV, Thompson EA, Perez EA.

PLoS One. 2015 Apr 30;10(4):e0127133. doi: 10.1371/journal.pone.0127133. eCollection 2015. No abstract available.

14.

Folate receptor-α (FOLR1) expression and function in triple negative tumors.

Necela BM, Crozier JA, Andorfer CA, Lewis-Tuffin L, Kachergus JM, Geiger XJ, Kalari KR, Serie DJ, Sun Z, Moreno-Aspitia A, O'Shannessy DJ, Maltzman JD, McCullough AE, Pockaj BA, Cunliffe HE, Ballman KV, Thompson EA, Perez EA.

PLoS One. 2015 Mar 27;10(3):e0122209. doi: 10.1371/journal.pone.0122209. eCollection 2015. Erratum in: PLoS One. 2015;10(4):e0127133. Aspita, Alvaro Moreno [corrected to Moreno-Aspitia, Alvaro].

15.

MEN1 mutations in Hürthle cell (oncocytic) thyroid carcinoma.

Kasaian K, Chindris AM, Wiseman SM, Mungall KL, Zeng T, Tse K, Schein JE, Rivera M, Necela BM, Kachergus JM, Casler JD, Mungall AJ, Moore RA, Marra MA, Copland JA, Thompson EA, Smallridge RC, Jones SJ.

J Clin Endocrinol Metab. 2015 Apr;100(4):E611-5. doi: 10.1210/jc.2014-3622. Epub 2015 Jan 27.

16.

Mutant KRAS-induced expression of ICAM-1 in pancreatic acinar cells causes attraction of macrophages to expedite the formation of precancerous lesions.

Liou GY, Döppler H, Necela B, Edenfield B, Zhang L, Dawson DW, Storz P.

Cancer Discov. 2015 Jan;5(1):52-63. doi: 10.1158/2159-8290.CD-14-0474. Epub 2014 Oct 31.

17.

Clinical and molecular features of Hürthle cell carcinoma of the thyroid.

Chindris AM, Casler JD, Bernet VJ, Rivera M, Thomas C, Kachergus JM, Necela BM, Hay ID, Westphal SA, Grant CS, Thompson GB, Schlinkert RT, Thompson EA, Smallridge RC.

J Clin Endocrinol Metab. 2015 Jan;100(1):55-62. doi: 10.1210/jc.2014-1634.

PMID:
25259908
18.

RNA sequencing identifies multiple fusion transcripts, differentially expressed genes, and reduced expression of immune function genes in BRAF (V600E) mutant vs BRAF wild-type papillary thyroid carcinoma.

Smallridge RC, Chindris AM, Asmann YW, Casler JD, Serie DJ, Reddi HV, Cradic KW, Rivera M, Grebe SK, Necela BM, Eberhardt NL, Carr JM, McIver B, Copland JA, Thompson EA.

J Clin Endocrinol Metab. 2014 Feb;99(2):E338-47. doi: 10.1210/jc.2013-2792. Epub 2013 Dec 2.

19.

Gene expression, single nucleotide variant and fusion transcript discovery in archival material from breast tumors.

Norton N, Sun Z, Asmann YW, Serie DJ, Necela BM, Bhagwate A, Jen J, Eckloff BW, Kalari KR, Thompson KJ, Carr JM, Kachergus JM, Geiger XJ, Perez EA, Thompson EA.

PLoS One. 2013 Nov 22;8(11):e81925. doi: 10.1371/journal.pone.0081925. eCollection 2013.

20.

An integrated model of the transcriptome of HER2-positive breast cancer.

Kalari KR, Necela BM, Tang X, Thompson KJ, Lau M, Eckel-Passow JE, Kachergus JM, Anderson SK, Sun Z, Baheti S, Carr JM, Baker TR, Barman P, Radisky DC, Joseph RW, McLaughlin SA, Chai HS, Camille S, Rossell D, Asmann YW, Thompson EA, Perez EA.

PLoS One. 2013 Nov 1;8(11):e79298. doi: 10.1371/journal.pone.0079298. eCollection 2013.

21.

Macrophage-secreted cytokines drive pancreatic acinar-to-ductal metaplasia through NF-κB and MMPs.

Liou GY, Döppler H, Necela B, Krishna M, Crawford HC, Raimondo M, Storz P.

J Cell Biol. 2013 Aug 5;202(3):563-77. doi: 10.1083/jcb.201301001.

22.

Deep Sequence Analysis of Non-Small Cell Lung Cancer: Integrated Analysis of Gene Expression, Alternative Splicing, and Single Nucleotide Variations in Lung Adenocarcinomas with and without Oncogenic KRAS Mutations.

Kalari KR, Rossell D, Necela BM, Asmann YW, Nair A, Baheti S, Kachergus JM, Younkin CS, Baker T, Carr JM, Tang X, Walsh MP, Chai HS, Sun Z, Hart SN, Leontovich AA, Hossain A, Kocher JP, Perez EA, Reisman DN, Fields AP, Thompson EA.

Front Oncol. 2012 Feb 10;2:12. doi: 10.3389/fonc.2012.00012. eCollection 2012.

23.

Detection of redundant fusion transcripts as biomarkers or disease-specific therapeutic targets in breast cancer.

Asmann YW, Necela BM, Kalari KR, Hossain A, Baker TR, Carr JM, Davis C, Getz JE, Hostetter G, Li X, McLaughlin SA, Radisky DC, Schroth GP, Cunliffe HE, Perez EA, Thompson EA.

Cancer Res. 2012 Apr 15;72(8):1921-8. doi: 10.1158/0008-5472.CAN-11-3142. Epub 2012 Apr 10.

24.

A novel bioinformatics pipeline for identification and characterization of fusion transcripts in breast cancer and normal cell lines.

Asmann YW, Hossain A, Necela BM, Middha S, Kalari KR, Sun Z, Chai HS, Williamson DW, Radisky D, Schroth GP, Kocher JP, Perez EA, Thompson EA.

Nucleic Acids Res. 2011 Aug;39(15):e100. doi: 10.1093/nar/gkr362. Epub 2011 May 27.

25.

Differential expression of microRNAs in tumors from chronically inflamed or genetic (APC(Min/+)) models of colon cancer.

Necela BM, Carr JM, Asmann YW, Thompson EA.

PLoS One. 2011 Apr 12;6(4):e18501. doi: 10.1371/journal.pone.0018501.

26.

MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer.

Andorfer CA, Necela BM, Thompson EA, Perez EA.

Trends Mol Med. 2011 Jun;17(6):313-9. doi: 10.1016/j.molmed.2011.01.006. Epub 2011 Mar 2. Review.

PMID:
21376668
27.

Misregulated E-cadherin expression associated with an aggressive brain tumor phenotype.

Lewis-Tuffin LJ, Rodriguez F, Giannini C, Scheithauer B, Necela BM, Sarkaria JN, Anastasiadis PZ.

PLoS One. 2010 Oct 27;5(10):e13665. doi: 10.1371/journal.pone.0013665.

28.

Peroxisome proliferator-activated receptor gamma down-regulates follistatin in intestinal epithelial cells through SP1.

Necela BM, Su W, Thompson EA.

J Biol Chem. 2008 Oct 31;283(44):29784-94. doi: 10.1074/jbc.M804481200. Epub 2008 Sep 3.

29.

Pathophysiological Roles of PPARgamma in Gastrointestinal Epithelial Cells.

Necela BM, Thompson EA.

PPAR Res. 2008;2008:148687. doi: 10.1155/2008/148687.

30.

The high affinity peroxisome proliferator-activated receptor-gamma agonist RS5444 inhibits both initiation and progression of colon tumors in azoxymethane-treated mice.

Su W, Necela BM, Fujiwara K, Kurakata S, Murray NR, Fields AP, Thompson EA.

Int J Cancer. 2008 Sep 1;123(5):991-7. doi: 10.1002/ijc.23640.

31.

Toll-like receptor 4 mediates cross-talk between peroxisome proliferator-activated receptor gamma and nuclear factor-kappaB in macrophages.

Necela BM, Su W, Thompson EA.

Immunology. 2008 Nov;125(3):344-58. doi: 10.1111/j.1365-2567.2008.02849.x. Epub 2008 Apr 18.

32.

Functional genomic analysis reveals cross-talk between peroxisome proliferator-activated receptor gamma and calcium signaling in human colorectal cancer cells.

Bush CR, Havens JM, Necela BM, Su W, Chen L, Yanagisawa M, Anastasiadis PZ, Guerra R, Luxon BA, Thompson EA.

J Biol Chem. 2007 Aug 10;282(32):23387-401. Epub 2007 Jun 12.

33.

Differential expression, distribution, and function of PPAR-gamma in the proximal and distal colon.

Su W, Bush CR, Necela BM, Calcagno SR, Murray NR, Fields AP, Thompson EA.

Physiol Genomics. 2007 Aug 20;30(3):342-53. Epub 2007 May 22.

PMID:
17519361
34.

Peroxisome proliferator-activated receptor gamma promotes epithelial to mesenchymal transformation by Rho GTPase-dependent activation of ERK1/2.

Chen L, Necela BM, Su W, Yanagisawa M, Anastasiadis PZ, Fields AP, Thompson EA.

J Biol Chem. 2006 Aug 25;281(34):24575-87. Epub 2006 Jun 30.

35.

RS5444, a novel PPARgamma agonist, regulates aspects of the differentiated phenotype in nontransformed intestinal epithelial cells.

Chen L, Bush CR, Necela BM, Su W, Yanagisawa M, Anastasiadis PZ, Fields AP, Thompson EA.

Mol Cell Endocrinol. 2006 Jun 7;251(1-2):17-32. Epub 2006 Mar 29.

PMID:
16574311
36.

Mechanisms of glucocorticoid receptor action in noninflammatory and inflammatory cells.

Necela BM, Cidlowski JA.

Proc Am Thorac Soc. 2004;1(3):239-46. Review. No abstract available.

PMID:
16113441
37.
38.
39.

Crystallization of the human glucocorticoid receptor ligand binding domain: a step towards selective glucocorticoids.

Necela BM, Cidlowski JA.

Trends Pharmacol Sci. 2003 Feb;24(2):58-61. Review.

PMID:
12559765
40.
43.

Supplemental Content

Loading ...
Support Center